剂量递增研究视角下FAPI放射性药物药代动力学的改善
在PC3荷瘤小鼠中开展剂量递增研究,将FAPI放射性示踪剂按10至1500 pmol给药并行生物分布与PET/CT显像,发现剂量从10 pmol增至600 pmol可显著降低血摄取并提高肿瘤摄取,350–600 pmol时效能最佳;[68Ga]Ga-DOTA.SA.FAPI人体研究显示脱靶摄取减少,与临床前结果一致。
要点
- PC3荷瘤小鼠中FAPI示踪剂剂量从10 pmol增至600 pmol显著降低血摄取并提高肿瘤摄取。
- 所有示踪剂在350–600 pmol时效能达峰,超过600 pmol药代动力学发生改变。
- [68Ga]Ga-DOTA.SA.FAPI人体研究显示胰腺、唾液腺、心脏等脱靶摄取减少。
核心结论
- 研究强调精确的FAPI放射性示踪剂剂量至关重要,可优化PET显像、减少辐射暴露并改善治疗,需考虑FAP生物学及sFAP对药代动力学的影响。
研究设计与样本
- 在PC3荷瘤小鼠中开展剂量递增研究,所有放射性示踪剂给药剂量为10至1500 pmol,随后进行生物分布与PET/CT显像。
- 通过生物分布和代谢物分析分别评估示踪剂对FAP、PREP和DPP4的选择性及体内稳定性。
- 用qPCR定量器官FAP表达,用ELISA测定小鼠和人血样中的循环FAP(sFAP)水平,并开展原理验证性人体研究。
主要发现
- 剂量从10 pmol增至600 pmol显著降低血摄取并提高肿瘤摄取,优化了体内性能。
- 所有放射性示踪剂在350–600 pmol时效能达峰,超过600 pmol后药代动力学发生改变。
- 生物分布研究证实所有示踪剂在PREP和DPP4抑制剂存在下仍对FAP具有体内选择性,并表现出显著体内稳定性。
- 多种器官中证实FAP表达,健康小鼠和人中均可定量sFAP。
- [68Ga]Ga-DOTA.SA.FAPI人体研究显示脱靶摄取减少(如胰腺、唾液腺、心脏),与临床前发现一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study explores the use of fibroblast activation protein inhibitors (FAPI) targeting radiopharmaceuticals as a new approach for pan-cancer treatment, focusing on key factors affecting their effectiveness. We hypothesized that adjusting the administered radiotracer dose one could enhance the tumor-to-background ratios. METHODS: In a dose-escalation study with PC3 xenografts, all radiotracers were administered at doses between 10 and 1500 pmol, followed by biodistribution and PET/CT imaging. Their selectivity towards FAP, PREP, and DDP4, along with their stability in vivo, was assessed by biodistribution and metabolite analysis, respectively. Organ FAP expression was quantified using qPCR, and circulating FAP (sFAP) levels were measured in mouse and human blood samples via ELISA. Proof-of-principle human studies were also conducted. RESULTS: Increasing the dose from 10 to 600 pmol significantly reduced blood uptake and enhanced tumor uptake, optimizing their in vivo performance. All radiotracers showed peak efficacy at 350-600 pmol, with altered pharmacokinetics beyond 600 pmol. Biodistribution studies validated the in vivo selectivity of all radiotracers towards FAP, even in the presence of PREP and DPP4 inhibitors, while they demonstrated remarkable stability in vivo. FAP expression was confirmed in various organs, with sFAP quantified in both healthy mice and humans. Human studies with [68Ga]Ga-DOTA.SA.FAPI revealed reduced off-target uptake (e.g., pancreas, salivary glands, heart), aligning with the preclinical findings. CONCLUSION: The study highlights the crucial need for precise FAPI-radiotracer dosing, optimizing PET imaging, reducing radiation exposure, and enhancing treatment by accounting for FAP biology and sFAP's influence on pharmacokinetics.
引用
- Bilinska A, Ballal S, Bal C, et al. Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40000459. doi:10.1007/s00259-025-07141-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。